13F-HR filed by Octagon Capital Advisors LP
Octagon Capital Advisors LP filed this 13F-HR for the quarter ended 2026-09-30, accepted by EDGAR 2026-11-16 19:22:34 UTC, with 26 holding rows worth $750,613,938.
- Accession
- 0001839435-26-000006
- Filer
- CIK 1839435
- Filed
- 2026-11-16
- Accepted by EDGAR
- Ingested
- Source
- EDGAR live feed
13F report for Q3 2026
A holdings report, 26 entries on the cover page, a total value of $750,613,938 stated on the cover page (in dollars after the unit check, H1), rows summing to $750,613,938 with VALUE read as dollars as filed, 13F file number 028-20958. The quarter's positions are built on this report. The resolved quarter.
The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).
| Issuer as filed | CUSIP | Class | Amount | Value | Value read as | Type |
|---|---|---|---|---|---|---|
| DIANTHUS THERAPEUTICS INC | 252828108 | COM | 1,686,667 | $148,511,029 | dollars as filed | |
| ABIVAX SA- | 00370M103 | SPONSORED ADS | 993,000 | $98,326,860 | dollars as filed | |
| DEFINIUM THERAPEUTICS INC | 24477V105 | COM SHS | 2,511,000 | $95,568,660 | dollars as filed | |
| COGENT BIOSCIENCES INC | 19240Q201 | COM | 2,350,000 | $75,247,000 | dollars as filed | |
| ARRIVENT BIOPHARMA INC | 04272N102 | COM | 2,141,387 | $64,841,198 | dollars as filed | |
| TAYSHA GENE THERAPIES INC | 877619106 | COMMON STOCK | 9,693,244 | $47,206,098 | dollars as filed | |
| Obsidian Therapeutics, Inc. | 67448A106 | Common Stock, $0.0001 par value per share | 2,414,610 | $33,152,595 | dollars as filed | |
| KYMERA THERAPEUTICS INC | 501575104 | COM | 205,000 | $22,916,950 | dollars as filed | |
| DISC MEDICINE INC COM | 254604101 | Stock | 270,000 | $17,674,200 | dollars as filed | |
| TANGO THERAPEUTICS INC | 87583X109 | COM | 630,000 | $15,718,500 | dollars as filed | |
| XENON PHARMACEUTICALS INC COM | 98420N105 | Stock | 420,000 | $15,619,800 | dollars as filed | |
| Adlai Nortye | 00704R109 | SPONSORED ADS | 934,716 | $14,955,456 | dollars as filed | |
| MIRUM PHARMACEUTICALS INC | 604749101 | COM | 169,450 | $14,484,586 | dollars as filed | |
| AKTIS ONCOLOGY INC | 01021M104 | COMMON STOCK | 713,000 | $13,882,110 | dollars as filed | |
| PALISADE BIO INC | 696389402 | COMMON STOCK | 10,276,317 | $13,873,028 | dollars as filed | |
| ERASCA INC | 29479A908 | CALL | 720,000 | $10,555,200 | dollars as filed | call |
| BIOAGE LABS INC COM | 09077V100 | Stock | 1,300,000 | $9,217,000 | dollars as filed | |
| PHARVARIS NV | N69605108 | COMMON STOCK | 249,000 | $7,898,280 | dollars as filed | |
| GYRE THERAPEUTICS INC | 403783103 | COMMON STOCK | 954,416 | $6,995,869 | dollars as filed | |
| DBV TECHNOLOGIES S A | 23306J309 | SPONSORED ADS | 574,200 | $6,752,592 | dollars as filed | |
| OCULAR THERAPEUTIX INC | 67576A100 | COM | 599,900 | $4,601,233 | dollars as filed | |
| TREVI THERAPEUTICS INC COM | 89532M101 | Stock | 315,000 | $4,510,800 | dollars as filed | |
| FAETH THERAPEUTICS INC | 81728A207 | COM NEW | 100,000 | $2,974,000 | dollars as filed | |
| PRECISION BIOSCIENCES INC | 74019P207 | COM NEW | 430,000 | $2,691,800 | dollars as filed | |
| UNICYCIVE THERAPEUTICS INC | 90466Y202 | COMMON STOCK | 275,000 | $1,291,125 | dollars as filed | |
| GOSSAMER BIO INC COM | 38341P102 | Stock | 96,875 | $1,147,969 | dollars as filed |
Amendment chain
| Filing | Role | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13F-HR 0001839435-26-000006 | this filing | 2026-11-16 |